GTPS - Greater Trochanteric Pain SyndromeHIPSNCT06297148
The HIP Self-management Study
A study testing Self-management in people with GTPS - Greater Trochanteric Pain Syndrome and Gluteal Tendinopathy, run by Oslo University Hospital at 1 site in Norway.
Trial summary
The HIPS-study will be an observer blinded, single-centre, parallel-group randomized controlled trial (RCT). The main purpose of the study is: 1. To investigate the clinical effectiveness of a self- management program versus usual care for patients with greater trochanteric pain syndrome (GTPS). Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- GTPS - Greater Trochanteric Pain Syndrome, Gluteal Tendinopathy, Trochanteric Bursitis
- What is being tested?
- Self-management
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 1 siteNorway
- Study dates
- 12 Mar 2024to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants between 18 and 70 years of age
- History of lateral hip pain > 3 months
- Reported average pain intensity the last week ≥ 3 on a numeric rating scale
- Lateral hip pain is the main complaint
- Pain on palpation of the greater trochanter region
- In addition, lateral hip pain on at least one of the following tests:
Show all 13Show fewer
- Single leg stance test: standing 30 seconds on the affected leg
- FADER: passive stretch/compression of gluteus medius/minimus
- FADER-R: static muscle test with resistance to internal hip rotation
- ADD: passive stretch to hip adduction in sidelying
- ADD-R: resisted hip abduction in sidelying
- FABER (Patrick's) test
- A positive test is defined as a spontaneous reproduction of the participant's lateral hip pain. In participants with bilateral lateral hip pain, the worst hip will be included, and the presence of bilateral pain will be documented.
Who cannot join
- Significant back pain causing referred pain to the lateral hip
- Clinical signs of radiculopathy
- Symptomatic osteoarthritis
- Other hip joint pathologies
- History of trauma or surgery on the affected side
- Pregnancy or post-partum pelvic pain (under 12 months since birth)
- Active cancer
- Not able to write, read, and comprehend Norwegian (without the use of an interpreter)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Self-management Program for Greater Trochanteric Pain Syndrome: a Randomized Controlled Trial
The HIPS-study will be an observer blinded, single-centre, parallel-group randomized controlled trial (RCT).
The main purpose of the study is:
Read more
- To investigate the clinical effectiveness of a self- management program versus usual care for patients with greater trochanteric pain syndrome (GTPS).
- H0: There is no difference between a self-management program and usual care on pain and function in patients with GTPS.
- H1: There is a difference between a self-management program and usual care on pain and function in patients with GTPS.
- To investigate if self-management is more cost-effective than usual care in the treatment of patients with GTPS.
Participants will be randomly allocated into one of two groups: 1) self-management program or 2) usual care.
Follow-up will be at 3-, 6- and 12-months.
Read the detailed description
Background:
Continuous or intermittent lateral hip pain, also known as greater trochanteric pain syndrome (GTPS), is a common chronic and disabling musculoskeletal condition. It usually occurs during the fourth to sixth decades of life, predominantly among women. The prevalence and incidence rates have been reported to be 4.2 and 3.3 per 1000 person-years, respectively, in the general practice population. The impact of GTPS is reported to be debilitation, as it typically disturbs sleep and limits daily function and participation in work.
Exercise and education are considered the cornerstone of treatment, and in recent randomized controlled trials this combination has demonstrated significant improvements in pain and function. However, studies have failed to show any difference between specific hip exercises and non-specific (sham) exercises in combination with patient education. As GTPS is recurrent and persistent of nature, person-centered care and the incorporation of self-management strategies could be beneficial. To the investigators knowledge, this study will be the first one to investigate self-management for the current patient population. Results from the study may change the type, delivery, and content of treatment for patients with GTPS, relevant for both primary- and secondary care.
The main objective of the study is to evaluate the clinical effectiveness of a self-management program compared to usual care for patients with GTPS.
Methods and analyses:
110 patients will be recruited and randomly allocated into one of two groups: 1) self-management or 2) usual care. The randomization sequence will be computer-generated with blocks of various size, unknown to any of the research team. Due to the nature of therapeutic studies, blinding of the participants and the treating physiotherapist is not possible. The investigator assessing the outcome measures will be blinded to group allocation.
Descriptive statistics will be collected at baseline, and presented as means with standard deviation (SD) or as medians with inter quartile range (IQR). The primary analysis will be conducted on the intention to treat population and compare the two intervention groups (self-management vs usual care) on mean difference in pain and disability (VISA-G-N score) at baseline, 3 and 6 months. The estimated mean difference between groups at 6 months (main endpoint) will be analyzed using a longitudinal mixed effects model analysis of covariance. Baseline score on VISA-G-N, time, intervention and interaction between time and intervention will be included as covariates. Secondary outcomes assessed at multiple time points (baseline, 3, 6 and 12 months) will be analyzed by the same approach as described for the primary outcome, on both the intention to treat population and the per protocol population.
The degree of missingness will be explored using sensitivity analysis with multiple imputation and/or the use of an alternative repeated measures mixed model analysis accordingly, to assess the robustness of data. In addition, multivariable logistic and linear regression analysis will be used to explore predictive factors, such as demographics, expectations, clinical findings, and psychosocial factors for primary and secondary outcomes. Model building will be done in a way that is appropriate for the given sample sizes, by restricting the number of potential predictive factors and considering shrinkage methods to stabilize predictions. Mediation analysis will be performed to explore the causal pathway between treatment allocation and the primary outcome of pain and disability by considering, amongst others, pain self-efficacy and emotional distress as potential mediators that may be part of the causal pathway between intervention and outcome.
- Conditions
- GTPS - Greater Trochanteric Pain Syndrome, Gluteal Tendinopathy, Trochanteric Bursitis, Lateral Hip Pain
- Being tested
- Self-management, Usual care
- Keywords
- Greater Trochanteric Pain Syndrome, Lateral hip pain, Gluteal tendinopathy, Trochanteric bursitis, Self-management
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Self-managementOther
Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.
Participants will have access to study material, including exercise alternatives and a podcast.
Usual careOther
Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
| Study group | Role | What they receive |
|---|---|---|
| Self-management | Experimental | The intervention will consist of 3-5 individual sessions over 12 weeks with a physiotherapist.
There will be 3 physiotherapists delivering the self-management intervention. Receives: Other: Self-management |
| Usual care | Active comparator | Given standardized information at baseline and free to choose further treatment in primary care. Receives: Other: Usual care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Victorian Institute of Sport Assessment Gluteal Questionnaire (VISA-G)
Pain and function. Total score ranges from 0-100, with higher scores representing less pain and disability.
Measured: Baseline, 3 months, 6 months, 12 months
Secondary outcomes (11)
Numeric rating scale (NRS)
Pain intensity (at rest and during activity) during the last week rated on a scale ranging from 0 (no pain) to 10 (worst possible pain).
Measured: Baseline, 3 months, 6 months, 12 months
Painful sites
The number of painful sites (during the last 14 days) divided into 18 anatomical regions. Number of painful sites are added up to give a total score.
Measured: Baseline, 3 months, 6 months, 12 months
The Pain Self-Efficacy Questionnaire (PSEQ)
Confidence in performing activities while in pain. Includes 10-items, where patients rate their confidence from 0 points (not at all confident) to 6 points (completely confident). Total scores are calculated by summing the individual items with a range from 0 points (less self-efficacy) to 60 points (more self-efficacy).
Measured: Baseline, 3 months, 6 months, 12 months
EuroQoL-5 dimensions-5 Level (Eq-5D-5L)
Generic health related quality of life. The first part is based on 5 questions which are answered on a 5-step scale. It gives an index between 0-1, with a higher index representing better quality of life. The second part, EQ-VAS is a vertical line in which the participants mark the point best describing their quality of life. The score ranges from 0-100, where 100 represents best and 0 worst imaginable health states.
Measured: Baseline, 3 months, 6 months, 12 months
Hopkins Symptoms checklist-10 (HSCL-10)
Psychological distress measured on a scale from 1 (not at all) to 4 (extremely). The mean score is calculated producing a range of scores from 1-4 where higher score corresponds to more psychological distress.
Measured: Baseline, 3 months, 6 months, 12 months
iMTA Medical Consumption Questionnaire (iMCQ)
Medical consumption and healthcare utilization. Not measured on a scale, but as total costs. This is estimated based on unit costs collected from national pricelists.
Measured: Baseline, 3 months, 6 months, 12 months
iMTA Productivity Cost Questionnaire (iPCQ)
The costs of productivity loss (absenteeism) are valued in hours, and can be translated by a standard cost price of productivity per hour.
Measured: Baseline, 3 months, 6 months, 12 months
Expectations related to VISA-G
Expected change in pain and function (from baseline to 6 months) related to VISA-G. Total score ranges from 0-100, with higher scores representing less pain and disability.
Measured: Baseline
Expectations on numeric rating scale (NRS)
Expected change in function and pain rated on a scale from 0 (no pain/full function) to10 (worst possible pain/function)
Measured: Baseline, 3 months, 6 months
Global rating of change (GROC)
Perceived change in lateral hip pain from baseline to follow-up at 6 months, measured on an 11-point likert scale ranging from -5 (much worse) to 5 (completely recovered)
Measured: 6 months
Patient acceptable symptom state (PASS)
Patient satisfaction with current symptom state, by asking the question: "Taking into account all the activities you have during your daily life, your level of hip pain, and also your functional impairment, do you consider that your current state is satisfactory?" The response options are "yes" or "no"
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2024
- Study start12 Mar 2024
- Primary completionOct 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GTPS - Greater Trochanteric Pain SyndromeStudies of the same condition, open and under way.
- More trials run by Oslo University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 110 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oslo University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Oslo Metropolitan University, Fysiofondet, University of Oslo
- Responsible party
- Principal investigator, Marianne Bakke Johnsen, Oslo University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06297148
- Sponsor's protocol ID
- 2023/590816
- Other IDs
- 2023
- Acronym
- HIPS
- Status last verified
- Jan 2026
- First submitted
- 29 Feb 2024
- Last updated
- 19 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data, that underlie the results reported in the study, will be available to interested researchers upon reasonable request. Proposals should be directed to the data custodian, principal investigator at mamari@oslomet.no.
Publications
Morin Melas T, Bjorneboe J, Juel NG, Wefring ML, Skatteboe S, Killingmo RM, Engebretsen KB, Rathleff MS, Oiestad BE, Soberg HL, Pripp AH, Brox JI, Johnsen MB. Self-management versus usual care for greater trochanteric pain syndrome (the HIPS trial): study protocol for a randomised controlled trial. BMJ Open. 2025 Apr 5;15(4):e090688. doi: 10.1136/bmjopen-2024-090688.
PubMed 40187788
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Self-management Program for Greater Trochanteric Pain Syndrome: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06297148
- Acronym / sponsor ID
- HIPS / 2023/590816
- Conditions
- GTPS - Greater Trochanteric Pain Syndrome, Gluteal Tendinopathy, Trochanteric Bursitis, Lateral Hip Pain
- Keywords
- Greater Trochanteric Pain Syndrome, Lateral hip pain, Gluteal tendinopathy, Trochanteric bursitis, Self-management
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 110 participants (estimated)
- Lead sponsor
- Oslo University HospitalUniversity, hospital or other
- Collaborators
- Oslo Metropolitan University, Fysiofondet, University of Oslo
- Study start
- 12 Mar 2024 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 7 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The HIPS-study will be an observer blinded, single-centre, parallel-group randomized controlled trial (RCT).
The main purpose of the study is:
- To investigate the clinical effectiveness of a self- management program versus usual care for patients with greater trochanteric pain syndrome (GTPS).
- H0: There is no difference between a self-management program and usual care on pain and function in patients with GTPS.
- H1: There is a difference between a self-management program and usual care on pain and function in patients with GTPS.
- To investigate if self-management is more cost-effective than usual care in the treatment of patients with GTPS.
Participants will be randomly allocated into one of two groups: 1) self-management program or 2) usual care.
Follow-up will be at 3-, 6- and 12-months.
Detailed description
Background:
Continuous or intermittent lateral hip pain, also known as greater trochanteric pain syndrome (GTPS), is a common chronic and disabling musculoskeletal condition. It usually occurs during the fourth to sixth decades of life, predominantly among women. The prevalence and incidence rates have been reported to be 4.2 and 3.3 per 1000 person-years, respectively, in the general practice population. The impact of GTPS is reported to be debilitation, as it typically disturbs sleep and limits daily function and participation in work.
Exercise and education are considered the cornerstone of treatment, and in recent randomized controlled trials this combination has demonstrated significant improvements in pain and function. However, studies have failed to show any difference between specific hip exercises and non-specific (sham) exercises in combination with patient education. As GTPS is recurrent and persistent of nature, person-centered care and the incorporation of self-management strategies could be beneficial. To the investigators knowledge, this study will be the first one to investigate self-management for the current patient population. Results from the study may change the type, delivery, and content of treatment for patients with GTPS, relevant for both primary- and secondary care.
The main objective of the study is to evaluate the clinical effectiveness of a self-management program compared to usual care for patients with GTPS.
Methods and analyses:
110 patients will be recruited and randomly allocated into one of two groups: 1) self-management or 2) usual care. The randomization sequence will be computer-generated with blocks of various size, unknown to any of the research team. Due to the nature of therapeutic studies, blinding of the participants and the treating physiotherapist is not possible. The investigator assessing the outcome measures will be blinded to group allocation.
Descriptive statistics will be collected at baseline, and presented as means with standard deviation (SD) or as medians with inter quartile range (IQR). The primary analysis will be conducted on the intention to treat population and compare the two intervention groups (self-management vs usual care) on mean difference in pain and disability (VISA-G-N score) at baseline, 3 and 6 months. The estimated mean difference between groups at 6 months (main endpoint) will be analyzed using a longitudinal mixed effects model analysis of covariance. Baseline score on VISA-G-N, time, intervention and interaction between time and intervention will be included as covariates. Secondary outcomes assessed at multiple time points (baseline, 3, 6 and 12 months) will be analyzed by the same approach as described for the primary outcome, on both the intention to treat population and the per protocol population.
The degree of missingness will be explored using sensitivity analysis with multiple imputation and/or the use of an alternative repeated measures mixed model analysis accordingly, to assess the robustness of data. In addition, multivariable logistic and linear regression analysis will be used to explore predictive factors, such as demographics, expectations, clinical findings, and psychosocial factors for primary and secondary outcomes. Model building will be done in a way that is appropriate for the given sample sizes, by restricting the number of potential predictive factors and considering shrinkage methods to stabilize predictions. Mediation analysis will be performed to explore the causal pathway between treatment allocation and the primary outcome of pain and disability by considering, amongst others, pain self-efficacy and emotional distress as potential mediators that may be part of the causal pathway between intervention and outcome.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Self-management | Experimental | Other: Self-managementThe intervention will consist of 3-5 individual sessions over 12 weeks with a physiotherapist. There will be 3 physiotherapists delivering the self-management intervention. |
| Usual care | Active comparator | Other: Usual careGiven standardized information at baseline and free to choose further treatment in primary care. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Participants between 18 and 70 years of age
- History of lateral hip pain > 3 months
- Reported average pain intensity the last week ≥ 3 on a numeric rating scale
- Lateral hip pain is the main complaint
- Pain on palpation of the greater trochanter region
Key exclusion criteria (8 listed)
- Significant back pain causing referred pain to the lateral hip
- Clinical signs of radiculopathy
- Symptomatic osteoarthritis
- Other hip joint pathologies
- History of trauma or surgery on the affected side
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Self-managementPatients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior. Participants will have access to study material, including exercise alternatives and a podcast. | Other | Self-management |
| Usual careUsual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted. | Other | Usual care |
Primary outcome
Victorian Institute of Sport Assessment Gluteal Questionnaire (VISA-G)
Time frame: Baseline, 3 months, 6 months, 12 months
Pain and function. Total score ranges from 0-100, with higher scores representing less pain and disability.
11 secondary outcomes
Numeric rating scale (NRS)
Time frame: Baseline, 3 months, 6 months, 12 months
Painful sites
Time frame: Baseline, 3 months, 6 months, 12 months
The Pain Self-Efficacy Questionnaire (PSEQ)
Time frame: Baseline, 3 months, 6 months, 12 months
EuroQoL-5 dimensions-5 Level (Eq-5D-5L)
Time frame: Baseline, 3 months, 6 months, 12 months
Hopkins Symptoms checklist-10 (HSCL-10)
Time frame: Baseline, 3 months, 6 months, 12 months
iMTA Medical Consumption Questionnaire (iMCQ)
Time frame: Baseline, 3 months, 6 months, 12 months
iMTA Productivity Cost Questionnaire (iPCQ)
Time frame: Baseline, 3 months, 6 months, 12 months
Expectations related to VISA-G
Time frame: Baseline
Expectations on numeric rating scale (NRS)
Time frame: Baseline, 3 months, 6 months
Global rating of change (GROC)
Time frame: 6 months
Patient acceptable symptom state (PASS)
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Derived from this study: PubMed 40187788Morin Melas T, Bjorneboe J, Juel NG, Wefring ML, Skatteboe S, Killingmo RM, Engebretsen KB, Rathleff MS, Oiestad BE, Soberg HL, Pripp AH, Brox JI, Johnsen MB. Self-management versus usual care for greater trochanteric pain syndrome (the HIPS trial): study protocol for a randomised controlled trial. BMJ Open. 2025 Apr 5;15(4):e090688. doi: 10.1136/bmjopen-2024-090688.
- Grimaldi A, Mellor R, Hodges P, Bennell K, Wajswelner H, Vicenzino B. Gluteal Tendinopathy: A Review of Mechanisms, Assessment and Management. Sports Med 2015;45(8):1107-19. (In eng). DOI: 10.1007/s40279-015-0336-5Link provided by the sponsor.
- Pianka MA, Serino J, DeFroda SF, Bodendorfer BM. Greater trochanteric pain syndrome: Evaluation and management of a wide spectrum of pathology. SAGE Open Med 2021;9:20503121211022582. (In eng). DOI: 10.1177/20503121211022582Link provided by the sponsor.
- Klontzas ME, Karantanas AH. Greater trochanter pain syndrome: a descriptive MR imaging study. Eur J Radiol 2014;83(10):1850-5. (In eng). DOI: 10.1016/j.ejrad.2014.06.009.Link provided by the sponsor.
- Fearon AM, Scarvell JM, Neeman T, Cook JL, Cormick W, Smith PN. Greater trochanteric pain syndrome: defining the clinical syndrome. Br J Sports Med 2013;47(10):649-53. (In eng). DOI: 10.1136/bjsports-2012-091565.Link provided by the sponsor.
- Lievense A, Bierma-Zeinstra S, Schouten B, Bohnen A, Verhaar J, Koes B. Prognosis of trochanteric pain in primary care. Br J Gen Pract 2005;55(512):199-204. (In eng).Link provided by the sponsor.
- Plinsinga ML, Coombes BK, Mellor R, et al. Psychological factors not strength deficits are associated with severity of gluteal tendinopathy: A cross-sectional study. Eur J Pain 2018;22(6):1124-1133. (In eng). DOI: 10.1002/ejp.1199.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual participant data, that underlie the results reported in the study, will be available to interested researchers upon reasonable request. Proposals should be directed to the data custodian, principal investigator at mamari@oslomet.no.
Related trials for GTPS - Greater Trochanteric Pain Syndrome
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs
Not yet recruiting
Comparing Standard Care Approaches for Greater Trochanteric Pain Syndrome in General Practice
Greater Trochanteric Pain Syndrome, Gluteal Tendinopathy
Not yet recruitingPhase 4
Emerging Indications for Hyperbaric Oxygen Treatment
Post-COVID-19 Condition, Ulcerative Colitis
Recruiting
HILT in Greater Trochanteric Pain Syndrome
Greater Trochanteric Pain Syndrome
Recruiting
Enhancing Exercise Adherence Among Patients With Lateral Hip Pain
Greater Trochanter Pain Syndrome, Hip Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Self-management in people with GTPS - Greater Trochanteric Pain Syndrome and Gluteal Tendinopathy, run by Oslo University Hospital at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Victorian Institute of Sport Assessment Gluteal Questionnaire (VISA-G) (time frame: Baseline, 3 months, 6 months, 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06297148, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.